|Bid||160.60 x 100|
|Ask||167.00 x 500|
|Day's Range||156.53 - 163.64|
|52 Week Range||71.46 - 167.00|
|PE Ratio (TTM)||227.57|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?
Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis drugs Kalydeco and Orkambi may drive the stock to an earnings beat in Q2.
Is Gilead Sciences (GILD) poised for a beat next week? Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street. Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion.